Bubs Australia (ASX:BUB) enrolled the 400th infant in its growth monitoring study, part of the requirement of the US Food and Drug Administration for the infant formula firm to secure permanent access to the US market, according to a Tuesday filing with the Australian bourse.
Bubs currently has a "temporary enforcement discretion" access to the US market, which would become permanent upon the US FDA's approval, anticipated for October 2025, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments